Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways.
about
Profile of palbociclib in the treatment of metastatic breast cancerTumor suppressor genes and their underlying interactions in paclitaxel resistance in cancer therapyThe role of T‑box genes in the tumorigenesis and progression of cancer (Review)The cell survival pathways of the primordial RNA-DNA complex remain conserved in the extant genomes and may function as proto-oncogenesEmerging therapies for breast cancerMolecular stratification of early breast cancer identifies drug targets to drive stratified medicineCyclin-dependent kinase 11(p110) (CDK11(p110)) is crucial for human breast cancer cell proliferation and growthBreast Cancer Survivorship Care: Targeting a Colorectal Cancer Education Intervention.MicroRNA-199a-3p suppresses glioma cell proliferation by regulating the AKT/mTOR signaling pathwayLung Master Protocol (Lung-MAP)-A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400.Overcoming Endocrine Resistance in Hormone-Receptor Positive Advanced Breast Cancer-The Emerging Role of CDK4/6 InhibitorsThe effects of anticancer drugs TSA and GSK on spermatogenesis in male miceA triterpenoid from wild bitter gourd inhibits breast cancer cellsConstitutive activation of STAT3 in breast cancer cells: A review.miR-29b and miR-198 overexpression in CD8+ T cells of renal cell carcinoma patients down-modulates JAK3 and MCL-1 leading to immune dysfunction.The small GTPase ADP-Ribosylation Factor 1 mediates the sensitivity of triple negative breast cancer cells to EGFR tyrosine kinase inhibitors.A genetic view of laryngeal cancer heterogeneityTargeting synthetic lethality between the SRC kinase and the EPHB6 receptor may benefit cancer treatment.Molecular mechanisms and mode of tamoxifen resistance in breast cancer.Triple negative breast cancer: shedding light onto the role of pi3k/akt/mtor pathway.PD 0332991, a selective cyclin D kinase 4/6 inhibitor, sensitizes lung cancer cells to treatment with epidermal growth factor receptor tyrosine kinase inhibitors.HR+, HER2- Advanced Breast Cancer and CDK4/6 Inhibitors: Mode of action, Clinical Activity, and Safety Profiles.Ribociclib (LEE011): Mechanism of Action and Clinical Impact of This Selective Cyclin-Dependent Kinase 4/6 Inhibitor in Various Solid Tumors.Direct repression of the oncogene CDK4 by the tumor suppressor miR-486-5p in non-small cell lung cancerG0S2 represses PI3K/mTOR signaling and increases sensitivity to PI3K/mTOR pathway inhibitors in breast cancer.Epoxyazadiradione suppresses breast tumor growth through mitochondrial depolarization and caspase-dependent apoptosis by targeting PI3K/Akt pathway.Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2- advanced breast cancer in the randomized MONALEESA-2 trial.The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells.GRAMD1B regulates cell migration in breast cancer cells through JAK/STAT and Akt signaling.E-cadherin loss induces targetable autocrine activation of growth factor signalling in lobular breast cancer
P2860
Q26747737-2ABD12F4-76D2-426F-B313-201E915F0882Q26768521-2CB3C3DF-55DD-4145-825E-563420670CF6Q28468370-73C5C387-6633-4017-B07A-2226DB8F311DQ28649653-4E34BF46-AC41-488E-9D9B-205B4A927020Q33617949-29801EEF-6D70-4BCE-BD54-FC413D0502C3Q33731350-AB289312-49AA-4378-B8DE-ECE4081748DEQ35626610-CA3976CB-1B7B-4A6E-895B-36B4639FD04EQ36143729-A85018D8-C5E8-4E38-8CA7-F1CF340999D8Q36278102-8D6E48B4-94D9-4744-B172-0DE753B5C02CQ36303134-CADF8660-C8A5-480C-99ED-A447FFB892B0Q36420373-3C097ED1-7D7A-492E-8829-1992A9EFA93DQ36595148-EBDA3517-F42B-4F34-9600-605FEC63B588Q36634632-7B7384E1-50DF-463F-B984-6380746107DCQ36711689-9E75873B-C4B3-48CA-BBE4-8D02E9FD883AQ36785683-27AA26A9-7E7D-4452-8646-D2F4599CDE16Q36839141-F7EA9BDC-EBF5-435B-AE80-FCD1408FFBB0Q36972817-9D1E0EC8-B083-426C-8580-400D4CECA9F7Q37580359-45E43F41-B5B4-47C5-B19A-4B7FBBF41AF1Q37608272-AF5F3509-0C96-42A4-9006-55831093CE27Q37645090-03A42BF8-0B1A-4238-812E-FC3FA18BC78FQ37709050-60A0CDD4-48C0-4508-B608-F64F2CAB8D59Q38866877-770E28FC-DBBC-4668-B378-A3A254C20DD1Q38870282-0F720987-7946-42D1-BEB2-501093D38CC6Q38885118-92142C44-618B-4CCB-BA81-701D525A1997Q42515055-9ED6EF92-3EB9-44C5-89F5-3374C97D3C55Q47196315-7FB0038D-0D8C-4C58-9109-BA740EFD3D3CQ48257534-E5D11DCE-183C-4FE3-BC47-B38E40037A6FQ55091523-0623AF2D-CACB-4F46-B145-037D77704C4BQ55446160-9380C830-20EA-40CE-BCB1-079B24C23B75Q58603744-19E909DD-79DD-4427-9616-9E8FF5DFE66B
P2860
Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways.
description
2014 nî lūn-bûn
@nan
2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Clinical potential of novel th ...... C, and PI3K/AKT/mTOR pathways.
@ast
Clinical potential of novel th ...... C, and PI3K/AKT/mTOR pathways.
@en
Clinical potential of novel th ...... C, and PI3K/AKT/mTOR pathways.
@nl
type
label
Clinical potential of novel th ...... C, and PI3K/AKT/mTOR pathways.
@ast
Clinical potential of novel th ...... C, and PI3K/AKT/mTOR pathways.
@en
Clinical potential of novel th ...... C, and PI3K/AKT/mTOR pathways.
@nl
prefLabel
Clinical potential of novel th ...... C, and PI3K/AKT/mTOR pathways.
@ast
Clinical potential of novel th ...... C, and PI3K/AKT/mTOR pathways.
@en
Clinical potential of novel th ...... C, and PI3K/AKT/mTOR pathways.
@nl
P2860
P356
P1476
Clinical potential of novel th ...... C, and PI3K/AKT/mTOR pathways.
@en
P2093
Sarah R Hosford
Todd W Miller
P2860
P304
P356
10.2147/PGPM.S52762
P577
2014-08-06T00:00:00Z